JAZZ - The Benefits of Medical Marijuana for Patients and Your Portfolio
Cannabis research -- even for medical purposes -- is highly restricted in the United States. But we have seen plenty of glimmers of hope about its benefits, and signals that cannabis can treat severe disease. Take, for instance, Jazz Pharmaceuticals' (NASDAQ: JAZZ) recent announcement of its acquisition of GW Phamaceuticals (NASDAQ: GWPH) . Through the deal, Jazz will bring cannabidiol-based Epidiolex, a treatment for certain types of seizures, into its portfolio.
Dr. Chanda Macias is a medical cannabis advocate, researcher, and dispensary owner. She joined Olivia Zitkus and Corinne Cardina of the Healthcare and Cannabis Bureau on a March 19 episode of Fool Live to talk about the medical benefits of marijuana, and why they're worth more investor attention.
For further details see:
The Benefits of Medical Marijuana, for Patients and Your Portfolio